Literature DB >> 11452842

A meta-analysis comparing the effectiveness of buprenorphine and methadone.

S L West1, K K O'Neal, C W Graham.   

Abstract

Increases in the use of illicit opiates have refocused attention on these drugs. One outgrowth of this attention has been the increased consideration of pharmacotherapies to provide alternatives to methadone maintenance. Buprenorphine is one new tool used in the attenuation of illicit opiate use. Like methadone, buprenorphine produces cross-tolerance to other opiates. However, it may have advantages over methadone including a longer duration, limited withdrawal syndrome, and increased safety. Buprenorphine's ability to serve as a replacement drug for illicit opiate use is well documented, and efforts have recently been made to compare the drug with methadone. The purpose of this study was to provide a meta-analysis of all available research reporting a controlled comparison of buprenorphine and methadone. This analysis provided a rating of the comparative efficacy of each drug, thus giving clinicians an additional guide when selecting an appropriate course of treatment. Findings suggest a relative equality in the efficacy of buprenorphine and methadone, although patients receiving methadone were less likely to test positive for illicit opiate use. Past experience with methadone maintenance acted as a moderating variable, however, such that those receiving buprenorphine were more likely to stay drug-free in studies that included patients with prior methadone experience.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11452842     DOI: 10.1016/s0899-3289(01)00054-2

Source DB:  PubMed          Journal:  J Subst Abuse        ISSN: 0899-3289


  14 in total

1.  Managing opioid dependence. Comparing buprenorphine with methadone.

Authors:  Chris Cavacuiti; Peter Selby
Journal:  Can Fam Physician       Date:  2003-07       Impact factor: 3.275

Review 2.  The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence.

Authors:  Steven Simoens; Catriona Matheson; Christine Bond; Karen Inkster; Anne Ludbrook
Journal:  Br J Gen Pract       Date:  2005-02       Impact factor: 5.386

3.  Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?

Authors:  M Pavlic; K Libiseller; P Grubwieser; W Rabl
Journal:  Int J Legal Med       Date:  2005-04-16       Impact factor: 2.686

4.  Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.

Authors:  Michael S Virk; Seksiri Arttamangkul; William T Birdsong; John T Williams
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

5.  Buprenorphine implant for opioid addiction.

Authors:  Walter Ling
Journal:  Pain Manag       Date:  2012-07

Review 6.  Misuse of and dependence on opioids: study of chronic pain patients.

Authors:  Meldon Kahan; Anita Srivastava; Lynn Wilson; Douglas Gourlay; Deana Midmer
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

Review 7.  Update on the clinical use of buprenorphine: in opioid-related disorders.

Authors:  Simon Ducharme; Ronald Fraser; Kathryn Gill
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

Review 8.  A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.

Authors:  Walter Ling
Journal:  J Neuroimmune Pharmacol       Date:  2016-03-23       Impact factor: 4.147

Review 9.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.